- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05276063
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) (LIDS)
July 20, 2023 updated by: Sling Therapeutics, Inc.
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
75
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cathy Radovich
- Phone Number: 734-887-9192
- Email: info@slingtx.com
Study Contact Backup
- Name: Robin Schmidt
- Phone Number: 734-887-9192
- Email: info@slingtx.com
Study Locations
-
-
-
North York, Canada, M3C 0G9
- Recruiting
- Toronto Retina Institute
-
Contact:
- Myuri Jeyabalachandran
- Email: mayuri.triresearch@gmail.com
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 3N9
- Recruiting
- Vancouver Coastal Health Eye Care Center
-
Contact:
- Namita Ramdin
- Email: namita.ramdin@vch.ca
-
-
-
-
-
Milan, Italy
- Recruiting
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Endocrinology Pawilione Zonda
-
Contact:
- Ilaria Muller
- Email: ilaria.muller@policlinico.mi.it
-
Pisa, Italy
- Recruiting
- University of Pisa
-
Contact:
- Poupak Fallahi
- Email: poupak.fallahi@unipi.it
-
Pisa, Italy
- Recruiting
- AOU Pisana
-
Contact:
- Giovanna Rotondo Dottore
- Email: ge.rd@hotmail.it
-
-
-
-
-
Barcelona, Spain, 08907
- Recruiting
- Hospital Universitari de Bellvitge
-
Contact:
- Mercè Badia
- Email: mbadiav.doo@gmail.com
-
Madrid, Spain, 28034
- Recruiting
- Hospital Universitario Ramon y Cajal
-
Contact:
- Noelia Oblanca
- Email: oblanca.noelia@gmail.com
-
Madrid, Spain, 28006
- Recruiting
- Hospital La Princesa
-
Contact:
- Carolina Knott
- Email: ck.nutricion@gmail.com
-
-
-
-
-
Camberley, United Kingdom, GU16 7UJ
- Recruiting
- Frimley Health Foundation Trust
-
Contact:
- Elizabeth Baker
- Email: elizabeth.baker@nhs.net
-
Cardiff, United Kingdom, CF14 4XN
- Recruiting
- Cardiff University
-
Contact:
- David Butler
- Email: David.Butler2@wales.nhs.uk
-
London, United Kingdom, EC1V 2PD
- Recruiting
- Moorfields Eye Hospital NIHR Clinical Research Facility
-
Contact:
- Amanda Davis
- Email: amanda.davis5@nhs.net
-
-
-
-
California
-
Beverly Hills, California, United States, 90210
- Recruiting
- Dr. Raymond Douglas Private Site
-
Contact:
- Ravleen Kaur
- Email: ravleen@raymonddouglasmd.com
-
La Jolla, California, United States, 92093
- Recruiting
- UC San Diego Health
-
Contact:
- Iliana Molina
- Email: imolina@health.ucsd.edu
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai
-
Contact:
- Denice Dubuclet
- Email: Denice.Dubuclet@cshs.org
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA
-
Contact:
- Pearl Heumann
- Email: PearlHeumann@mednet.ucla.edu
-
Palo Alto, California, United States, 94303
- Recruiting
- Byers Eye Institute - Stanford University
-
Contact:
- Farheen Shaikh
- Email: fqshaikh@stanford.edu
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Bascom Palmer Eye Institute
-
Contact:
- Karla Olivas
- Email: kxo265@med.miami.edu
-
Sarasota, Florida, United States, 34239
- Recruiting
- Sarasota Retina Institute
-
Contact:
- Peggy Jelemensky
- Email: srqresearch@aol.com
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Mass Eye and Ear
-
Contact:
- Iris Xiao-Hong
- Email: Xiao-Hong_Wen@meei.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Recruiting
- Kellogg Eye Center
-
Contact:
- James Green
- Email: greenjw@med.umich.edu
-
Livonia, Michigan, United States, 48152
- Recruiting
- Kahana Oculoplastic & Orbital Surgery
-
Contact:
- Neema Sunny
- Email: neema@mioculoplastics.com
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Hans-Abram Voges
- Email: Voges.Hans-Abram@mayo.edu
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Recruiting
- Washington University in St. Louis/Barnes Jewish Hospital
-
Contact:
- Jolene Brasher
- Email: bjolene@wustl.edu
-
-
New York
-
New York, New York, United States, 10032
- Not yet recruiting
- Columbia University
-
Contact:
- Marzhan Atakulova
- Email: ma3448@cumc.columbia.edu
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Baptist Health Eye Center
-
Contact:
- Tina Robbins
- Email: cjrobbin@wakehealth.edu
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health and Science University
-
Contact:
- Mitchell Schain
- Email: schainm@ohsu.edu
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Recruiting
- Neuro-Eye Clinical Trials, Inc.
-
Contact:
- Laura Perez
- Email: lperez@neuroeye.com
-
-
Utah
-
Salt Lake City, Utah, United States, 84102
- Recruiting
- Eyelid Center of Utah
-
Contact:
- Alyssa Crooks
- Email: acrooks@entcenterslc.com
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Recruiting
- West Virginia University Eye Institute
-
Contact:
- Athena Echols
- Email: athena.sparks@wvumedicine.org
-
-
Wisconsin
-
Madison, Wisconsin, United States, 57305
- Recruiting
- University of Wisconsin
-
Contact:
- Kris Dietzman
- Email: kadietzman@wisc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinical diagnosis of Graves' Disease and/or autoimmune Hashimoto's thyroiditis associated with active moderate to severe TED with a CAS ≥ 4 (on the 7- item scale) for the most severely affected eye (primary study eye) at Screening and Baseline
- Confirmed active TED (not sight-threatening but has an appreciable impact on daily life, with onset (as determined by patient records) within 12 months prior to the Baseline visit and usually associated with one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia.
- Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine levels [FT3] < 50% above or below the normal limits) at Screening.
- Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Screening and is not planning for any such treatment during the course of the study.
Exclusion Criteria:
- Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months.
- Corneal decompensation unresponsive to medical management.
- Previous orbital irradiation or orbital surgery.
- Any glucocorticoid use (intravenous [IV] or oral) with a cumulative dose equivalent to >= 1g of methylprednisolone or equivalent for the treatment of TED within 3 months of Screening.
- Prior IGF-1R inhibitor therapy for any condition.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo Arm
|
Placebo taken twice daily by mouth
|
Active Comparator: Low Dose
Active Arm Low Dose Linsitinib
|
Study medication taken twice daily by mouth
|
Active Comparator: High Dose
Active Arm High Dose Linsitinib
|
Study medication taken twice daily by mouth
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Subjects who are Proptosis Responders at Week 24
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in Proptosis to Week 24 (Study Eye)
Time Frame: 24 weeks
|
24 weeks
|
Percentage of Subjects who are Diplopia Responders at Week 24
Time Frame: 24 weeks
|
24 weeks
|
Percentage of Subjects who are Overall Responders at Week 24
Time Frame: 24 weeks
|
24 weeks
|
Percentage of Subjects who are CAS Categorical Responders at Week 24 (Study Eye)
Time Frame: 24 weeks
|
24 weeks
|
Change from Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24.
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Estimated)
July 1, 2023
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
March 2, 2022
First Submitted That Met QC Criteria
March 2, 2022
First Posted (Actual)
March 11, 2022
Study Record Updates
Last Update Posted (Actual)
July 21, 2023
Last Update Submitted That Met QC Criteria
July 20, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VGN-TED-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eye Diseases
-
University of Alabama at BirminghamPfizerCompletedVision | Eye Disease | Eye CareUnited States
-
TBF Genie TissulaireCompletedEnucleated; Eye | Eye CancerFrance
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
National Eye Institute (NEI)RecruitingInherited Eye DiseaseUnited States, United Kingdom, China, Pakistan, Philippines, Ukraine, India, Italy
-
National Eye Institute (NEI)Recruiting
-
National Eye Institute (NEI)RecruitingGenetic Eye DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
OptovueCompletedNo Eye DiseaseUnited States, United Kingdom
-
National Eye Institute (NEI)CompletedHereditary Eye DiseaseUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States